Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–39 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: acamprosate (Campral) Clear all
Completed Phase 2 Interventional Results available

Medication Development in Alcoholism: Acamprosate Versus Naltrexone

NCT00656630
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Naltrexone, Placebo
Drug
Lead sponsor
The Scripps Research Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Acamprosate to Reduce Symptoms of Alcohol Withdrawal

NCT00106106
View directory record Official record
Conditions
Alcohol-Related Disorders, Alcohol Dependence, Alcoholism, Healthy Volunteer
Interventions
NMR-spectroscopy, Oral acamprosate
Procedure · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
21 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Phase 3 Interventional

COMBINE (Acamprosate/Naltrexone)

NCT00006206
View directory record Official record
Conditions
Alcoholism
Interventions
naltrexone (Revia), acamprosate (Campral)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
1,375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
12
States / cities
New Haven, Connecticut • Miami, Florida • Belmont, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Acamprosate vs. Placebo in Bipolar Alcoholics

NCT00466661
View directory record Official record
Conditions
Alcohol Dependence, Bipolar Disorder
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Phase 1 Interventional

Clinical Trial of Acamprosate for Tinnitus

NCT00596531
View directory record Official record
Conditions
Tinnitus
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 8, 2016 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

An 8 Week Open-Label Study to Evaluate the Efficacy and Safety of Acamprosate Calcium (Campral) as Augmentation Therapy in Patients With Anxiety Symptoms Who Are Only Partial Responders to SSRI or SNRI Antidepressants

NCT00591565
View directory record Official record
Conditions
Anxiety
Interventions
Acamprosate
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 64 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Acamprosate in Alcoholics With Comorbid Anxiety or Depression

NCT00330174
View directory record Official record
Conditions
Alcohol Dependence, Major Depression, Social Anxiety Disorder, Generalized Anxiety Disorder
Interventions
Acamprosate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 60 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
3
States / cities
Belmont, Massachusetts • New York, New York • Pickens, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Acamprosate in Youth With Fragile X Syndrome

NCT01300923
View directory record Official record
Conditions
Fragile X Syndrome, Autism Spectrum Disorders
Interventions
Acamprosate
Drug
Lead sponsor
Indiana University
Other
Eligibility
5 Years to 17 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 2, 2026, 4:59 PM EDT
Terminated No phase listed Observational

Promoting Medications for Alcohol Use Disorder on the General Medicine Service

NCT04287790
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
audit and feedback, educational meetings, and academic detailing to promote medication receipt, Acamprosate, naltrexone, or disulfiram
Behavioral · Drug
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic

NCT00381043
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Acamprosate (Campral)
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Oct 2, 2026, 4:59 PM EDT
Not yet recruiting Not applicable Interventional

A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease

NCT07553377
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Associated Liver Disease, Medications for Alcohol Use Disorder, Behavioral Medicine, Medication Adherence
Interventions
AcamproSync
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome

NCT03818191
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Acamprosate, Placebo
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Center City, Minnesota • Rochester, Minnesota • Newberg, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Acamprosate in Fragile x Syndrome

NCT01911455
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
acamprosate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 23 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism

NCT00452543
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Abuse, Alcohol Dependence
Interventions
acamprosate, escitalopram, Medical management, Placebo
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 2, 2026, 4:59 PM EDT
Completed Phase 1 Interventional

Study of Acamprosate in Autism

NCT01813318
View directory record Official record
Conditions
Autistic Disorder
Interventions
Acamprosate, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 17 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 2, 2026, 4:59 PM EDT